NEW YORK (TheStreet) -- Eli Lilly (LLY) was the latest company to come under fire for drug pricing and there's no way to know who's next, Credit Suisse senior analyst Vamil Divan said on CNBC's "Power Lunch" on Tuesday afternoon.
"Why has the price of Humalog insulin gone up 700% in 20 years? It's simple. The drug industry's greed," Senator Bernie Sanders (I-VT) tweeted out this afternoon.
If he was asked which drug would be the subject of Sander's scrutiny today, Humalog would not have been one of his choices despite covering the industry closely since insulin pricing has been challenging recently due to competition, Divan said. "There's many, many other products that are much, much more expensive that I think people could raise reasonable concerns about."
The risk of having a microscope put on certain drug prices is a "general risk" across the pharma sector today, he noted. "Across all drugs there's some degree of this 'which drug gets pulled out next or which class.' I think that's what's unknowable."
Recently, Mylan (MYL) came under fire for the price of its life-saving EpiPen drug. Last year, Martin Shkreli's Turing Pharmaceutical's Daraprim pricing was questioned.
However, the net price of Humalog has actually only gone up in the low single digits year-over-year, Divan pointed out. Sander's figures don't account for the rebates and discounts on the drug. "But it is certainly a hop-on issue. It's gotten a lot of press and a lot of public support around doing something. So it gets a lot of attention."
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings team rates Eli Lilly & Co as a Buy with a ratings score of B+. This is driven by multiple strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks the team covers.
You can view the full analysis from the report here: LLYLLY data by YCharts